BioCentury | Aug 2, 2019
Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

...It gained rights to the CLN6 gene therapy when it acquired Nationwide Children's Hospital spinout Celenex...
...other forms of Batten disease, and marked the start of Amicus' gene therapy program (see "Celenex...
BioCentury | May 29, 2019
Company News

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

...deal further strengthens Amicus' gene therapy pipeline, which it began building with the acquisition of Celenex...
...hopes to reach 5,000 patients and generate $1 billion in global sales by 2023 (see "Celenex...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...ND $195 Boehringer Ingelheim GmbH ViraTherapeutics GmbH 9/13/18 ND ND $243 Amicus Therapeutics Inc. (NASDAQ:FOLD) Celenex...
BioCentury | Sep 21, 2018
Company News

Celenex takeout first of several expected Amicus gene therapy deals

...its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex...
...the deal, with Amicus planning to in-license additional gene therapies in the coming months. Via Celenex...
...NYSE:NVS; SIX:NOVN) acquired for about $8.7 billion this year. In addition to the upfront payment, Celenex...
BioCentury | Sep 20, 2018
Company News

Celenex takeout first of several planned gene therapy deals for Amicus

...its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex...
...the deal, with Amicus planning to in-license additional gene therapies in the coming months. Via Celenex...
...NYSE:NVS; SIX:NOVN) acquired for about $8.7 billion this year. In addition to the upfront payment, Celenex...
Items per page:
1 - 5 of 5
BioCentury | Aug 2, 2019
Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

...It gained rights to the CLN6 gene therapy when it acquired Nationwide Children's Hospital spinout Celenex...
...other forms of Batten disease, and marked the start of Amicus' gene therapy program (see "Celenex...
BioCentury | May 29, 2019
Company News

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

...deal further strengthens Amicus' gene therapy pipeline, which it began building with the acquisition of Celenex...
...hopes to reach 5,000 patients and generate $1 billion in global sales by 2023 (see "Celenex...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...ND $195 Boehringer Ingelheim GmbH ViraTherapeutics GmbH 9/13/18 ND ND $243 Amicus Therapeutics Inc. (NASDAQ:FOLD) Celenex...
BioCentury | Sep 21, 2018
Company News

Celenex takeout first of several expected Amicus gene therapy deals

...its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex...
...the deal, with Amicus planning to in-license additional gene therapies in the coming months. Via Celenex...
...NYSE:NVS; SIX:NOVN) acquired for about $8.7 billion this year. In addition to the upfront payment, Celenex...
BioCentury | Sep 20, 2018
Company News

Celenex takeout first of several planned gene therapy deals for Amicus

...its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex...
...the deal, with Amicus planning to in-license additional gene therapies in the coming months. Via Celenex...
...NYSE:NVS; SIX:NOVN) acquired for about $8.7 billion this year. In addition to the upfront payment, Celenex...
Items per page:
1 - 5 of 5